TY - JOUR
T1 - Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection
T2 - A comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and β2-microglobulin
AU - Stein, Daniel S.
AU - Lyles, Robert H.
AU - Graham, Neil M.H.
AU - Tassoni, Charles J.
AU - Margolick, Joseph B.
AU - Phair, John P.
AU - Rinaldo, Charles
AU - Detels, Roger
AU - Saah, Alfred
AU - Bilello, John
N1 - Funding Information:
Johns Hopkins University School of Hygiene and Public Health (Baltimore): Alfred J. Saah, Principal Investigator; Haroutune Armenian, Homayoon Farzadegan, Donald R. Hoover, Nancy Kass, Joseph Margolick, Justin McArthur, Ellen Taylor. Howard Brown Health Center and Northwestern University Medical School (Chicago): John P. Phair, Principal Investigator; Joan S. Chmiel, Bruce Cohen, Maurice O’Gorman, Daina Variakojis, Jerry Wesch, Steven M. Wolinsky. University of California, Los Angeles, Schools of Public Health and Medicine: Roger Detels, Principal Investigator; Barbara R. Visscher, Janice P. Dudley, John L. Fahey, Janis V. Giorgi, Oto Martínez-Maza, Eric N. Miller, Hal Morgenstern, Par-unag Nishanian, John Oishi, Jeremy Taylor, Harry Vinters. University of Pittsburgh Graduate School of Public Health (Pittsburgh): Charles R. Rinaldo, Principal Investigator; Roger Anderson, James T. Becker, Phalguni Gupta, Monto Ho, Lawrence Kingsley, John Mellors, Oliver Ndimbie, Sharon Riddler, Anthony Silvestri, Sharon Zucconi. Data Coordinating Center, Johns Hopkins University School of Hygiene and Public Health: Alvaro Muñoz, Principal Investigator; Baibai Chen, Clara Chu, Cheryl Enger, Stephen Gange, Lisa P. Jacobson, Cynthia Kleeberger, Robert Lyles, Steven Piantadosi, Sol Su. NIH (Bethesda, MD): National Institute of Allergy and Infectious Diseases: Lewis Schrager, Project Officer; National Cancer Institute: Sandra Melnick.
Funding Information:
Received 18 February 1997; revised 17 June 1997. All subjects gave written informed consent, and the MACS protocol was approved by the Institutional Review Board of each institution in accordance with the guidelines of the US Department of Health and Human Services. Financial support: NIH (AI-15104, AI-35042, AI-35043, AI-35040, AI-35041, AI-37984, AI-35039, AI-37613, and RR-00722). Reprints or correspondence: Dr. Daniel S. Stein, Clinical Pharmacology Studies Unit, A-142, Albany Medical College, 47 New Scotland Ave., Albany, NY 12208. * Present affiliations: Glaxo-Wellcome, Inc., Research Triangle Park, North Carolina (N.M.H.G.); RW Johnson Pharmaceutical Research Institute, Raritan, New Jersey (C.J.T.); Merck & Co., Inc., West Point, Pennsylvania (A.S.). †Multicenter AIDS Cohort Study investigators are listed after text.
PY - 1997
Y1 - 1997
N2 - Quantification of human immunodeficiency virus (HIV) RNA by branched- chain DNA signal amplification, measurement of soluble tumor necrosis factor type II receptors (sTNFR-II), neopterin, β2-microglobulin, or CD4 cell counts can be used to predict the risk of clinical progression or death in HIV infection but have not been compared in the same study. Ninety subjects were categorized into progression groups by their rate of CD4 cell decline and matched into triplets by initial CD4 cell count, age, race, and calendar time. By matched logistic regression, only the sTNFR-II and HIV RNA values were predictive of outcome across the progression groups. Categorization of baseline HIV RNA and sTNFR-II resulted in differences in progression to several clinical outcomes. sTNFR-II concentrations were the only immune marker examined that increased the prognostic utility of HIV RNA determination in early-stage subjects. Further studies in later stages of disease or after therapy are indicated.
AB - Quantification of human immunodeficiency virus (HIV) RNA by branched- chain DNA signal amplification, measurement of soluble tumor necrosis factor type II receptors (sTNFR-II), neopterin, β2-microglobulin, or CD4 cell counts can be used to predict the risk of clinical progression or death in HIV infection but have not been compared in the same study. Ninety subjects were categorized into progression groups by their rate of CD4 cell decline and matched into triplets by initial CD4 cell count, age, race, and calendar time. By matched logistic regression, only the sTNFR-II and HIV RNA values were predictive of outcome across the progression groups. Categorization of baseline HIV RNA and sTNFR-II resulted in differences in progression to several clinical outcomes. sTNFR-II concentrations were the only immune marker examined that increased the prognostic utility of HIV RNA determination in early-stage subjects. Further studies in later stages of disease or after therapy are indicated.
UR - http://www.scopus.com/inward/record.url?scp=16944362070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16944362070&partnerID=8YFLogxK
U2 - 10.1086/514108
DO - 10.1086/514108
M3 - Article
C2 - 9359714
AN - SCOPUS:16944362070
SN - 0022-1899
VL - 176
SP - 1161
EP - 1167
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 5
ER -